Topics

Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad

06:03 EDT 18 Sep 2019 | ChinaBio Today

Shanghai Pharmaceuticals formed a JV with Russian biopharma Biocad that will include an initial investment of $250 million and is expected to lead to a $2.8 billion capitalization. The JV will develop six Biocad monoclonal antibodies targeting cancer and autoimmune diseases for China's market, some or them novel drugs and the rest biosimilars. The initial $250 million investment will underwrite China clinical trials. Originally announced via an MOU signed last year, the partnership was formally inaugurated early this summer in a Moscow ceremony. More details....

Stock Symbol: (HK: 2605)

Share this with colleagues:

Original Article: Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad

NEXT ARTICLE

More From BioPortfolio on "Shanghai Pharma Forms $250 Million China Antibody JV with Russia's Biocad"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...